Here are my notes from the last couple of management interactions.
30-12-2020 (CNBC)
- 12 launches till date; FY22 will be much better in terms of sales than FY21
- Number of platforms that Lupin has been working on is one of the highest in the industry (complex generics, injectable, inhalers, biosimilar, specialty)
- Q4FY21 EBITDA margins should be >20%
- Somerset inspection went badly
13-01-2021 (JP Morgan)
- 16 ANDA approvals and 13 FDA filings in CY20
- Albuterol market share stands at 8% of generic market share in Q3FY21 (is manufactured at Pithampur)
- Somerset inspection was challenging
- Expect to file 1 out of the 2 liposomal product in partnership with ForDoz
- Have one of the largest portfolio of in-licensed products that are sold in India
- Aim to move from the current rank of 6 to 3 in the Indian pharma market over the next few years
- Have invested substantially in 3 major areas – inhalation, biosimilar & long acting complex injectables
- Specialty business: women health in US and Canada; gastrointestinal in Canada, neurology in Europe
Disclosure: Invested (position size here)